Transdermal Patch Moisture-Triggered Membrane for Alkaline Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Transdermal therapeutic systems face challenges with stability-sensitive and volatile active ingredients, leading to uncontrolled release, skin irritation, and degradation, particularly with alkaline active ingredients, which result in reduced efficacy and shelf-life issues.
Innovation Solution
A transdermal therapeutic system comprising a backing layer, an active ingredient layer with an alkaline active ingredient salt and a polymeric component, and a moisture-permeable membrane layer, where the active ingredient is released only by skin moisture, ensuring controlled delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If continuous drying at elevated temperature is used during production, then production efficiency is improved, but active ingredient losses occur due to volatility and thermal instability
Solution Approach 1:
The patent changes the drying parameters by using ambient temperature or lower temperatures instead of elevated temperatures, and uses airflow circulation instead of continuous high-heat drying. This resolves the contradiction by maintaining production efficiency through controlled drying while preventing thermal degradation and volatility losses of the active ingredient.
Solution Approach 2:
The patent implements periodic or intermittent drying cycles with airflow circulation rather than continuous high-temperature drying. This allows moisture removal while giving the active ingredient periods of stability, preventing cumulative thermal damage and volatility losses while still achieving adequate drying for production efficiency.
2Reliability
If alkaline active ingredient is used in transdermal system, then therapeutic effectiveness is improved, but uncontrolled release and skin irritation occur
Solution Approach 1:
The patent introduces a membrane layer as an intermediary between the alkaline active ingredient reservoir and the skin. This membrane controls the release rate, preventing direct contact and uncontrolled delivery of the alkaline substance to the skin, thereby maintaining therapeutic effectiveness while eliminating skin irritation and uncontrolled release.
Solution Approach 2:
The patent changes the physical state and delivery parameters of the alkaline active ingredient by enclosing it in a membrane-controlled system. This transforms uncontrolled release into controlled, sustained delivery, maintaining therapeutic effectiveness while preventing the harmful effects of direct alkaline contact with skin.
3Manufacturing precision
If membrane layer is added to control active ingredient delivery, then delivery control is improved, but device complexity increases
Solution Approach 1:
The patent uses a thin, flexible membrane layer to control active ingredient delivery. This thin-film approach provides precise delivery control through the membrane's selective permeability while adding minimal structural complexity compared to bulk or rigid control systems.
Solution Approach 2:
The patent extracts the delivery control function into a separate, dedicated membrane layer that can be independently optimized and manufactured. This modular approach allows precise control of active ingredient delivery while keeping the overall device structure relatively simple through functional separation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a stable and controlled release of active ingredients over two years, reducing skin irritation and side effects, while maintaining high bioavailability and compatibility, and minimizing active ingredient wastage.
Implementation Method 1
a moisture-permeable membrane layer (M), wherein the active ingredient (W) is released from the active ingredient layer (R) only as a result of the moisture from the active component (WK), which migrates in from the outside through the membrane layer (M)
Implementation Method 2
via the connection of the membrane, and owing to the diffusion, enriches the adhesive layer (K) with high concentrations of active ingredient
Data Source
AI summary
The invention relates to a transdermal therapeutic system made of the following layers: a carrier layer (T), an active ingredient layer (R), a membrane layer (M) and optionally an adhesive layer (K), wherein the carrier layer (T) is impenetrable to the active substance and to water, the active substance layer (R) comprises as an active substance component the salt of an alkali reactive active substance, such as a CNS-active amine in combination with at least one alkali reactive further component, and a polymer component (P1), wherein the active substance is released from the active substance layer (R) only by the moisture entering from the exterior through the membrane layer (M), and the membrane layer (M) is made of a polymer component (P2), allowing a uniform delivery of basic active substances to the skin.